ACSL3

Across TCGA pan-cancer cohorts, ACSL3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ACSL3 data layer compared with 29 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher ACSL3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACSL3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA and UCEC are the cancer types where ACSL3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	II,III,IV	0.163	0.525	.013	12	view →
UCEC	DFS	Median	All	0.961	0.627	.026	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ACSL3–ESCA (DFS)

Open the ESCA breakdown →